Drummond, Mark W.

Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia

Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research

Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research

Cited by 352

Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution

Rodriguez-Meira, A., Norfo, R., Wen, S., Chédeville, A. L., Rahman, H., O’Sullivan, J., Wang, G., Louka, E., Kretzschmar, W. W., Paterson, A., et al. (2023) · Nature Genetics

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 158

Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., et al. (2016) · Haematologica

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 91

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2012) · Blood

Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research

Cited by 20